newsfilter
← Latest News
GlobeNewswire·

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease